Stocks Health care AZN
NYSE · Health careAstrazeneca PLC (AZN)
Astrazeneca PLC reported revenue of $58.7B in fiscal 2025, up 8.6% from a year earlier. Net income was $10.2B, a net margin of 17.4%. Operating cash flow minus capital spending left $11.8B of free cash flow in fiscal 2025. At December 31, 2025 it held $5.7B in cash against $29.6B of debt.
Key facts about Astrazeneca PLC
- Net worth
- Astrazeneca PLC has a market value (market cap) of $256.5B at the latest share price, and shareholders' equity of $48.7B on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $58.7B (+8.6% year on year), with net income of $10.2B.
- Cash flow
- In fiscal 2025 operations brought in $14.6B of cash; after $2.8B of capital spending, free cash flow was $11.8B.
What Astrazeneca PLC does
AstraZeneca is a biopharmaceutical company that discovers, develops, and manufactures prescription medicines. Its treatments focus on oncology, cardiovascular diseases, renal conditions, and respiratory ailments. Its products are sold to hospitals, healthcare providers, and pharmacies globally. Its shares trade on NYSE under the ticker AZN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $58.7B | $10.2B | $6.54 | $11.8B |
| 2024 | $54.1B | $7B | $4.50 | $9.9B |
| 2023 | $45.8B | $6B | $3.81 | $9B |
| 2022 | $44.4B | $3.3B | $2.11 | $8.7B |
| 2021 | $37.4B | $112M | $0.08 | $4.9B |
| 2020 | $26.6B | $3.2B | $2.44 | $3.8B |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where AZN ranks in Health care
Dividends
It paid out $5B in cash dividends, 49% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | n/a | $5B | 49% |
| 2024 | n/a | $4.6B | 66% |
| 2023 | n/a | $4.5B | 75% |
| 2022 | n/a | $4.4B | 133% |
| 2021 | n/a | $3.9B | 3,443% |
| 2020 | n/a | $3.6B | 112% |
Latest SEC filings
What Astrazeneca PLC has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 5, 2026
- October 2, 2026
- October 1, 2026
- October 1, 2026
- September 29, 2026
- September 23, 2026
- September 21, 2026
- September 21, 2026
- September 18, 2026
- September 15, 2026
Insider trades
What the people running Astrazeneca PLC did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $3.2K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 6, 2026 | Sharma ManiSee remarks | Received as pay | 2 | $319.6 |
| September 8, 2026 | Sharma ManiSee Remarks | Received as pay | 1 | $162.6 |
| August 8, 2026 | Sharma ManiSee Remarks | Bought | 20 | $3.2K |
| August 6, 2026 | Sharma ManiSVP, Group Controller | Received as pay | 2 | $326.7 |
| July 6, 2026 | Sharma ManiSee Remarks | Received as pay | 2 | $380.9 |
| June 8, 2026 | Sharma ManiSee Remarks | Received as pay | 1 | $179.8 |
| May 20, 2026 | Sharma ManiSee Remarks | Sold | 11,893 | $2.2M |
| May 6, 2026 | Sharma ManiSee Remarks | Received as pay | 1 | $186.3 |
Who owns AZN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| AstraZeneca Holdings B.V.13D, may seek influence with 1 related filers | 22.4% | November 16, 2023 |
| AstraZeneca PLC13G, passive with 1 related filers | 7.8% | February 6, 2026 |
| Vanguard Capital Management13G, passive | 5.02% | April 28, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 1,472 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Evelyn Partners Group Ltd | 2,237,205 | new |
| Investor AB | 51,587,810 | 0 |
| Vanguard Capital Management LLC | 45,386,190 | +346,048 |
| Capital International Investors | 34,576,070 | +183,057 |
| Norges Bank | 33,864,172 | new |
| Capital World Investors | 30,075,134 | +1,810,554 |
| Fmr LLC | 28,895,264 | -706,460 |
| Wellington Management Group Llp | 28,537,243 | +4,786,158 |
| Legal & General Group Plc | 25,750,245 | -99,733 |
| Jpmorgan Chase & Co | 19,204,823 | +613,901 |
| VANGUARD ASSET MANAGEMENT, Ltd | 18,712,920 | +177,605 |
| Primecap Management Co | 18,095,178 | -118,530 |
| Bank of America Corp | 17,690,462 | -1,367,865 |
| Prudential PLC | 170,573 | +5,510 |
| Amundi | 16,422,784 | +1,036,635 |
| Franklin Resources Inc | 16,511,727 | -1,280,434 |
| Vanguard Fiduciary Trust Co | 13,291,085 | +95,907 |
| Deutsche Bank AG\ | 12,640,672 | +510,948 |
| Jupiter Topco LLC | 11,866,013 | new |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 11,720,479 | -1,218,125 |
Insiders
1 insiders reported holding 19,291 shares in total, about $3.2M at the last price.
| Holder | Shares |
|---|---|
| Sharma ManiSee remarks | 19,291 |
Questions about AZN
What does Astrazeneca PLC do?
AstraZeneca is a biopharmaceutical company that discovers, develops, and manufactures prescription medicines. Its treatments focus on oncology, cardiovascular diseases, renal conditions, and respiratory ailments. Its products are sold to hospitals, healthcare providers, and pharmacies globally. Its shares trade on NYSE under the ticker AZN.
What is Astrazeneca PLC's net worth?
Astrazeneca PLC has a market value (market cap) of $256.5B at the latest share price, and shareholders' equity of $48.7B on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Astrazeneca PLC profitable?
Yes. In fiscal 2025 it reported net income of $10.2B on revenue of $58.7B, a net margin of 17.4%.
How much revenue does Astrazeneca PLC make?
In fiscal 2025 Astrazeneca PLC reported revenue of $58.7B. That is 8.6% more than a year earlier.
When did Astrazeneca PLC last report?
Its newest filing of any kind is the insider trade from October 8, 2026.
Similar companies
Compare AZN with
Follow AZN
Get an email when Astrazeneca PLC files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Astrazeneca PLC tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.